Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura

Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare but life-threatening condition. In 2018, the nanobody caplacizumab was approved for the treatment of adults experiencing an acute episode of aTTP, in conjunction with plasma exchange (PEX) and immunosuppression for a minimum of 30 days af...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Völker, Linus A., Kaufeld, Jessica, Miesbach, Wolfgang, Brähler, Sebastian, Reinhardt, Martin, Kühne, Lucas, Mühlfeld, Anja, Schreiber, Adrian, Gaedeke, Jens, Tölle, Markus, Jabs, Wolfram J., Özcan, Fedai, Markau, Silke, Girndt, Matthias, Bauer, Frederic, Westhoff, Timm H., Felten, Helmut, Hausberg, Martin, Brand, Marcus, Gerth, Jens, Bieringer, Markus, Bommer, Martin, Zschiedrich, Stefan, Schneider, Johanna, Elitok, Saban, Gawlik, Alexander, Gäckler, Anja, Kribben, Andreas, Schwenger, Vedat, Schoenermarck, Ulf, Roeder, Maximilian, Radermacher, Jörg, Bramstedt, Jörn, Morgner, Anke, Herbst, Regina, Harth, Ana, Potthoff, Sebastian A., von Auer, Charis, Wendt, Ralph, Christ, Hildegard, Brinkkoetter, Paul T., Menne, Jan
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Thrombosis and Hemostasis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7362370/
https://ncbi.nlm.nih.gov/pubmed/32634236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001973
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados